26 July 2018 
EMA/CHMP/549796/2018 
Committee for Medicinal Products for Human Use (CHMP) 
Assessment report 
Procedure No. EMEA/H/C/WS1406 
Medicinal products authorised through the centralised procedure 
Invented name: 
International 
non-proprietary 
name/Common name: 
Product-specific application 
number 
Abseamed 
Binocrit 
Epoetin alfa Hexal 
epoetin alfa 
epoetin alfa 
epoetin alfa 
EMEA/H/C/000727/WS1406/0070 
EMEA/H/C/000725/WS1406/0070 
EMEA/H/C/000726/WS1406/0069 
Worksharing applicant (WSA): Sandoz GmbH 
Note  
Assessment report as adopted by the CHMP with all information of a commercially confidential nature 
deleted. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table of contents 
1. Background information on the procedure .............................................. 4 
1.1. Type II variation .................................................................................................. 4 
1.2. Steps taken for the assessment of the product ........................................................ 5 
2. Scientific discussion ................................................................................ 5 
2.1. Introduction ........................................................................................................ 5 
2.2. Clinical efficacy .................................................................................................... 7 
2.2.1. Methods and results .......................................................................................... 7 
2.2.2. Discussion ........................................................................................................ 8 
2.3. Clinical safety ...................................................................................................... 8 
2.4. Methods and results ............................................................................................. 8 
2.5. Discussion ......................................................................................................... 10 
2.6. Risk management plan ....................................................................................... 10 
2.7. Update of the Product information ........................................................................ 14 
3. Benefit-Risk Balance ............................................................................. 14 
4. Recommendations ................................................................................. 15 
5. EPAR changes ....................................................................................... 16 
Assessment report  
EMA/CHMP/549796/2018 
Page 2/16 
 
  
  
 
 
 
List of abbreviations 
 Committee for Medicinal Products for Human Use 
 Chronic Kidney Disease 
 Chronic Renal Failure  
 Darbepoetin  
 Direct Healthcare Professional Communication  
 Commission Regulation  
 European Economic Area 
 Erythropoietin 
CHMP 
CKD 
CRF 
DAR 
DHPC 
EC 
EEA 
EPO 
ESMO   European Society of Medical Oncology  
 Erythropoiesis-stimulating agent 
ESA 
 European Union 
EU 
 European Medicines Agency 
EMA 
 European Public Assessment Report 
EPAR 
 Gram 
g 
 Guideline on Good Pharmacovigilance Practices 
GVP 
Hb 
 Hemoglobin 
HX575   Binocrit/Epoetin alfa HEXAL/Abseamed 
ICSRs   individual case safety reports  
 UseInternational units 
IU 
 Intravenous 
i.v. 
 Kilogram 
kg 
 Liter 
L 
 Marketing Authorization Holder 
MAH 
 Marketing authorization 
MA 
 Myelodysplastic syndrome 
MDS 
 Milliliter 
mL 
 Micromol 
mmol 
 Not Applicable 
N/A 
 National Comprehensive Cancer Network  
NCCN 
 Post-Authorization Safety Study  
PASS 
 Pre-Filled Syringe 
PFS 
 Pharmacocinetic  
PK 
 Pharmacodynamic 
PD 
 Package Leaflet 
PL 
 Pure Red Cell Aplasia 
PRCA 
 Periodic Safety Update Report 
PSUR 
 Package leaflet 
PL 
 Red Blood Cells  
RBCs 
 Risk Management Plan  
RMP 
SCARs   Severe Cutaneous Adverse Reactions  
SmPC   Summary Product Caracteristics 
SJS 
s.c 
TEN 
 Stevens Johnson Syndrome  
 Subcutaneous 
 Toxic Epidermal Necrolysis  
WSA 
 Worksharing applicant 
Assessment report  
EMA/CHMP/549796/2018 
Page 3/16 
 
  
  
 
 
1.  Background information on the procedure 
1.1.  Type II variation 
Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Sandoz GmbH submitted to the 
European Medicines Agency on 3 May 2018 an application for a variation following a worksharing procedure 
according to Article 20 of Commission Regulation (EC) No 1234/2008.  
The following variation was requested: 
Variation requested 
Type 
Annexes 
affected 
C.I.2.b  
C.I.2.b - Change in the SPC, Labelling or PL of a 
Type II 
I, IIIA, IIIB 
generic/hybrid/biosimilar products following assessment of 
and A 
the same change for the reference product - Change(s) 
require to be further substantiated by new additional data 
to be submitted by the MAH  
Extension of indication to include the treatment of symptomatic anaemia (haemoglobin concentration of 
≤ 10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have 
low serum erythropoietin (< 200 mU/ml) for Binocrit, Epoetin alfa Hexal and Abseamed; as a consequence, 
sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated with safety and efficacy information. The Package Leaflet 
and the risk management plan (version 17.0) are updated in accordance. In addition, the worksharing 
applicant (WSA) took the opportunity to align information with the reference medicinal product and with the 
EC guideline on Excipients, to improve the quality and readability of the translations in the product 
information and to update the Annex A in line with EMA guideline. 
The requested worksharing procedure proposed amendments to the Summary of Product Characteristics, 
Labelling, Package Leaflet and Annex A and to the Risk Management Plan (RMP). 
Information on paediatric requirements 
Not applicable. 
Information relating to orphan market exclusivity 
Similarity 
Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 
847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised 
orphan medicinal products because there is no authorised orphan medicinal product for a condition related 
to the proposed indication. 
Scientific advice 
The applicant did not seek Scientific Advice at the CHMP. 
Assessment report  
EMA/CHMP/549796/2018 
Page 4/16 
 
  
  
 
 
 
1.2.  Steps taken for the assessment of the product 
Appointed (Co-)Rapporteurs for the WS procedure:  
Alexandre Moreau 
Timetable 
Submission date 
Start of procedure: 
CHMP Rapporteur Assessment Report 
PRAC members comments 
PRAC Outcome 
CHMP members comments 
Updated CHMP Rapporteur Assessment Report 
Opinion 
2.  Scientific discussion 
2.1.  Introduction 
Actual dates 
3 May 2018 
28 May 2018 
27 June 2018 
N/A 
12 July 2018 
16 July 2018 
19 July 2018 
26 July 2018 
Binocrit/Abeseamed/Epoetin Hexal alfa (HX575) is developed by Sandoz GmbH for the treatment of patients 
with anaemia. The active substance of HX575 is epoetin alfa, a recombinant protein expressed in Chinese 
hamster ovary cells whose amino acid sequence is identical to human urinary glycoprotein hormone 
erythropoietin (EPO), and is supposed to be functionally indistinguishable from endogenous human EPO. 
EPO is a growth factor produced primarily by the kidney in response to hypoxia that stimulates red blood cell 
production. EPO receptors may be expressed on the surface of a variety of tumour cells. 
HX575 in pre-filled syringes (PFS) is a biosimilar epoetin alfa product to Erypo/Eprex. It was originally 
approved in Aug 2007 and a renewal was obtained in June 2012. Based on the totality of the evidence, 
biosimilarity between HX575 and the reference product was established in the original development 
program, in terms of similar physicochemical and biological/functional properties, similar clinical PK and PD 
profiles, efficacy and safety data. 
Current indications 
Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF): 
in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis (see 
section 4.4). 
in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal 
origin accompanied by clinical symptoms in patients (see section 4.4).  
Binocrit is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple 
myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g. cardiovascular status, 
pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of 
transfusion requirements.  
Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. 
Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range 
Assessment report  
EMA/CHMP/549796/2018 
Page 5/16 
 
  
  
 
 
between 10 to 13 g/dl [6.2 to 8.1 mmol/l], no iron deficiency), if blood saving procedures are not available 
or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units 
of blood for females or 5 or more units for males). 
Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high 
perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should 
be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 
g/dl or 6.2 to 8.1 mmol/l) who do not have an autologous predonation programme available and with 
expected moderate blood loss (900 to 1,800 ml).  
Proposed additional indication 
Binocrit is indicated for the treatment of symptomatic anaemia (haemoglobin concentration of ≤ 10 g/dl) in 
adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum 
erythropoietin (< 200 mU/ml). 
Myelodyplasic syndrome disease  
Myelodysplastic syndromes comprise a group of clinically heterogeneous clonal bone marrow stem cell 
disorders. MDS is characterized by ineffective hematopoiesis, cytopenias (particularly anemia), and cellular 
dysfunctions. Cytopenias may eventually cause other symptoms, including asthenia and dyspnea as a result 
of anemia. Risk of infections may result from neutropenia, and bruising or spontaneous bleeding may result 
from thrombocytopenia. The natural course of MDS is highly variable, with overall survival ranging from a 
few weeks to several years due to various prognostic subtypes. MDS is primarily a disease of the elderly, 
with a median age at diagnosis of 70 years. The incidence in Europe is approximately 4 cases per 100,000 
per year, reaching 40-50 per 100,000 in patients aged 70 years and older. 
Rationale proposed change 
Approximately 60-80 percent of the patients with MDS experience symptomatic anemia, which can 
significantly reduce quality of life and increase morbidity, and often requires repeated blood transfusions. 
Controlling anemia and improving quality of life are the principal aims of treatment in lower risk MDS 
patients, while in the intermediate and high risk groups the goal is rather the prevention of complications of 
other severe cytopenias, or even reduction in MDS potential for leukemic evolution. Until recently, no 
vitamin supplementation was effective for MDS patients presenting mostly as anemic. RBC transfusions 
have until recently been the only approved treatment option and limited to the anemia component of MDS; 
however, these carry the risk of immunogenicity and iron overload, which are known to be associated with 
significant morbidity and mortality.  
In 2014 the European Society of Medical Oncology (ESMO) Guideline for MDS treatment recommended ESAs 
for the treatment of anemia associated with low risk MDS, especially with low serum epoetin level. The 
recent National Comprehensive Cancer Network (NCCN) Guideline for MDS treatment (2018) in the US now 
also supports the use of ESAs, including epoetin alfa as initial treatment in low risk MDS without 5q partial 
chromosomal deletion and with low serum epoetin level. 
The MAH indicated that this variation application is in agreement with the following EMA guidelines: 
•  Guideline on similar biological medicinal products (EMEA/CHMP/437/04 Rev. 1). In which is reported 
that:"If biosimilarity has been demonstrated in one indication, extrapolation to other indications of 
the reference product could be acceptable with appropriate scientific justification." 
•  Guideline on similar biological medicinal products containing biotechnology-derived proteins as 
active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev. 1). This 
guideline mentioned that: "In case the reference medicinal product has more than one therapeutic 
indication, the efficacy and safety of the biosimilar has to be justified or, if necessary, demonstrated 
Assessment report  
EMA/CHMP/549796/2018 
Page 6/16 
 
  
  
separately for each of the claimed indications. Justification will depend on, e.g., clinical experience, 
available literature data, mechanisms of action of the active substance of the reference product in 
each indication (including its degree of certainty), and on receptors iinvolved." 
Guideline on non-clinical and clinical development of similar biological medicinal products containing 
recombinant erythropoietins (Revision) (EMEA/CHMP/BMWP/301636/2008 Corr.). This guideline mentioned 
that "Since the mechanism of action of epoetin is the same for all currently approved indications and there 
is only one known epoetin receptor, demonstration of efficacy and safety in renal anaemia will allow 
extrapolation to other indications of the reference medicinal product with the same route of administration." 
2.2.  Clinical efficacy 
2.2.1.  Methods and results 
The applicant provided a scientific justification for extrapolation of indication in the following sections.  
-  Mode of action of epoetin alfa 
Epoetin  is  a  glycoprotein  hormone  produced  primarily  by  the  kidney  in  response  to  hypoxia;  it  is  a  key 
regulator  of  the  production  of  red  blood  cells  (RBCs).  Epoetin  is  involved  in  all  phases  of  erythroid 
development in the bone marrow, and has its principal effect at the level of erythroid precursors. Epoetin 
binds to its cell surface receptor and activates signal transduction pathways that interfere with apoptosis and 
also  stimulates  erythroid  cell  proliferation.  Recombinant  human  epoetin  alfa  is  an  ESA  that  works  by 
stimulating  the  production  of  RBCs  mimicking  the  physiological  action  of  the  endogenous  hormone.  The 
mode of action of epoetin alfa is the same for all approved indications and there is only one known epoetin 
receptor (EMEA/CHMP/BMWP/301636/2008 Corr.), whether to correct anaemia in various indications with 
different corresponding doses, or to protect from future anaemia in pre-surgery indications. 
-  Biosimilarity between HX575 and the reference product 
HX575 in pre-filled syringes (PFS) is a biosimilar epoetin alfa product to Erypo/Eprex. The first commercially 
available recombinant epoetin was epoetin alfa/Eprex. Based on the totality of the evidence, biosimilarity 
between HX575 and the reference product was established in the original development program, in terms of 
similar physicochemical and biological/functional properties, similar clinical PK and PD profiles, efficacy and 
safety data. Based on this, the MA was initially granted in the following indications: 
• 
• 
• 
• 
for the treatment of symptomatic anaemia associated with chronic renal failure 
for the treatment of chemotherapy-induced anaemia and reduction of transfusion requirements 
for surgery patients in an autologous blood donation program 
for patients scheduled for orthopaedic surgery. 
-  Key efficacy results of the EPOANE 3021 study conducted with the reference product in MDS 
patients 
Study  EPOANE  3021  was  a  randomized  1:2,  double-blind,  placebo-controlled,  multicentre  clinical  trial 
investigating  the  efficacy  and  safety  of  Eprex  as  a  treatment  for  anemia  in  adult  patients  with  low  or 
intermediate-1-risk MDS, as classified by an International Prognostic Scoring System. Results showed that 
31.8% of the 85 patients treated with epoetin alfa achieved the primary endpoint of erythroid response (per 
International Working Group 2006 response criteria) lasting at least 8 weeks by Week 24, compared with 
4.4% of the 45 patients treated with placebo (p<0.001). 
An ad-hoc analysis of the erythroid response time distribution over the total 52 weeks study duration was 
conducted by a Response  Review Committee and confirmed a statistically significant difference between 
Assessment report  
EMA/CHMP/549796/2018 
Page 7/16 
 
  
  
treatment groups, with 45.9% of the patients in the epoetin alfa group achieving an erythroid response 
compared  with  4.4%  of  the  patients  in  the  placebo  group  (p<0.001).  The  analysis  also  showed  that  all 
responding patients had low serum epoetin <200 IU/mL, and that higher proportions of responders were 
found among patients with lower prognostic risk and with lower pre-treatment transfusion needs. 
The mean erythroid response duration for patients treated with epoetin alfa was 192.3 days, with a median 
weekly dose of 730.4 IU/kg over 24 weeks. The number of patients requiring transfusion in the epoetin alfa 
group steadily decreased from 51.8% in the 8 weeks prior to baseline to 24.7% by Week 24. Transfusion 
need remained unchanged in patients treated with placebo (48.9% to 54.1%) over 24 weeks. The time to 
first transfusion was significantly longer in the epoetin alfa group (p=0.046). Epoetin alfa treatment also 
showed a statistically significant improvement of quality of life in responding patients (EPOANE 3021 Clinical 
Study Synopsis). 
2.2.2.  Discussion 
This Application is a type II variation to extend the indications of HX575 to the treatment of symptomatic 
anaemia  (haemoglobin  concentration  of  10≤  g/dL=  in  adult  with  low-  or  intermediate-  1  risk  primary 
myelodysplastic  syndromes  (MDS)  and  low  serum  erythropoietin  (<200  IU/mL).  This  last  indication  was 
approved for the originator product (Eprex/Erypo) through the Mutual Recognition Procedure with France 
acting as RMS in 2017.  
The  initial  originator  Application  was  mainly  based  on  the  EPOANE  3021  study.  Since  the  exclusivity 
protection for EPOANE 3021 data has been granted for the period of one year, the MAH is submitting a type 
II variation after the one-year exclusivity being expired. 
This variation is overall in agreement with the following EMA guidelines:  
- 
- 
- 
guideline on similar biological medicinal products (EMEA/CHAMP/437/04 Rev. 1). 
 guideline on similar medicinal products containing biotechnology-derived proteins as active substance: 
non-clinical and clinical issues (EMEA/CHAMP/BMWP/42832/2005 Rev. 1). 
guideline  on  non-clinical  and  clinical  development  of  similar  biological  medicinal  products  containing 
recombinant erythropietins (Revision) (EMEA/CHMP/BMWP/301636/2008 Corr.). 
According  to  guideline  on  similar  biological  medicinal  products,  biosimilarity  between  HX575  and  the 
reference  product  has  been  already  demonstrated  in  at  least  one  pivotal  indication.  The  scientific 
justification provided to extrapolate the biosimilary to the other indication is appropriate. 
Overall, the efficacy and safety of HX575 is justified by the mechanism of action of the active substance of 
the reference product which is the same in each approved indication. Consequently, the efficacy and safety 
similarity which was mainly demonstrated in renal anaemia patients allow an extrapolation to the extension 
of indication of the reference medicinal product with the same route of administration. 
2.3.  Clinical safety 
2.4.  Methods and results 
-  Overview of safety – post-marketing safety data 
HX575 is currently approved in all countries of European Economic area (EEA). It has since received 
marketing authorization in 37 non EEA countries via national registration. 
The extensive post-marketing safety data of HX575 as compiled in Sandoz’s global safety database are 
estimated to cover 283,227,200 patient-days (by 31-Aug-2017). Based on the post-marketing data sources 
Assessment report  
EMA/CHMP/549796/2018 
Page 8/16 
 
  
  
such as spontaneous individual case safety reports (ICSRs), including reports from healthcare professionals, 
consumers, scientific literature, and competent authorities (worldwide) and from solicited 
non-interventional ICSRs including those from non-interventional studies, it can be concluded that the 
safety profile of HX575 remains to be positive and in line with the previous cumulative experience and the 
safety information provided in the reference safety information for erythropoietin. 
The  recent  PSUR  version  11.0  reported  that  the  benefit/risk  assessment  remains  favourable.  The  RMP 
provided with this type II variation was updated. Further details on these and on safety data from the EU 
HX575-507  Post-Authorization  Safety  Study  (PASS)  study  in  chronic  kidney  disease  (CKD)  patients 
(currently ongoing) and the EPOANE 3021 study in MDS patients are provided throughout below. The MAH 
reported that the routine pharmacovigilance activities will continue upon approval of treatment with HX575 
in MDS patients. 
Information on reported adverse events (including deaths and serious adverse events) is regularly collected 
and assessed by Sandoz for all marketed epoetin alfa products (including originator and other biosimilar 
products, and not only those marketed by Sandoz). Relevant publications containing important new safety 
information associated with erythropoietin are also reviewed in PSURs. During the review period of PSUR 
11.0,  there  were  no  articles  concerning  new  and  significant  safety  findings,  pregnancy,  compassionate 
supply  and  named  patient  use,  lack  of  efficacy,  overdose,  abuse  of  misuse,  medication  error,  and 
non-clinical use. 
The established safety profile of the approved indications of HX575 is summarized in the Binocrit: EPAR – 
Product Information. Contraindications, special warnings and precautions for use are essentially the same as 
for  Erypo/Eprex.  No  new  or  unknown  adverse  events  for  the  class  of  drug  were  observed  for  HX575. 
Undesirable effects are described in Section 4.8 of the current SmPC. 
-  Study HX575-507 and antibody-induced pure red cell aplasia (PRCA) 
Currently epoetins alfa products are marketed by Sandoz in the EU for several indications. PRCA has been 
previously identified as a safety concern with subcutaneous usage in chronic kidney disease patients. Since 
March 2016, HX575 has been authorized for the s.c. route of administration in patients with CKD-induced 
anemia (in addition to the i.v. mode of administration). 
To further collect safety data of HX575 and to fulfil the post approval commitment, the Non-Interventional 
Post-Authorization  Safety  Study  (NI-PASS)  HX575-507  was  initiated  in  2017  as  appropriate  measure  to 
identify  any  risk  associated  with  the  s.c.  administration  route  of  HX575  in  CKD  patients  under  real-life 
post-approval conditions, including PRCA risk, a known treatment effect of the reference product. 
This NI-PASS study concept was discussed and agreed upon with the EMA in March 2016 and is part of the 
EU RMP. This is in addition to the standard pharmacovigilance reporting, which will include the reporting of 
potential  antibody-induced  PRCA  cases.  The  study  will  report  the  safety  data  of  2500  patients  over  24 
months with HX575 s.c. treatment.  
Spontaneous reports of 10 cases of antibody-induced PRCA with the marketed product were received until 
31-Aug-2017. Antibody-mediated PRCA has been reported after months to years of subcutaneous epoetin 
treatment  mainly  in  chronic  renal  failure  patients.  Causality  assessment  in  these  cases  is  hampered  by 
limited information and confounding factors. 
Cases of PRCA in patients with hepatitis C virus treated with interferon are known from the literature1. The 
current Company Core Data Sheet states that cases have also been reported in patients with hepatitis C 
treated with interferon and ribavirin, when ESAs are used concomitantly. Epoetin alpha is not approved in 
the management of anaemia associated with hepatitis C. 
1 Rossert J, Yue S, Smirnakis K, et al (2014)] Risk of pure red cell aplasia in patients with C receiving antiviral therapy and an 
erythropoiesis-stimulating agent. Clin Gastroenterol Hepatol; 12(2):341-5. 
Assessment report  
EMA/CHMP/549796/2018 
Page 9/16 
 
  
  
                                                
-  Studies HX575-307 and HX575-308 
Two  clinical  trials  were  recently  conducted  with  HX575  s.c.  in  CKD  patients  with  anemia;  both  were 
completed in Oct 2014.  
Study HX575-308 was conducted in Europe and assessed the incidence of antibody formation against HX575 
(s.c.  administration),  thus  furthering  the  safety  profile  of  HX575.  Study  HX575-  308  was  a  single  arm 
prospective multicenter study conducted in Europe with the primary objective to evaluate the safety and the 
immunogenicity  of  HX575  (s.c.  administration;  HX575  low-tungsten  syringes)  over  52  weeks,  thus 
furthering the safety profile of HX575 in 416 patients. 
Study HX575-307 investigated the incidence of antibody formation against HX575 and the safety profile of 
HX575 compared to the US-licensed epoetin alfa Epogen/Procrit (in vials; product not approved in Europe, 
designed for US). Study HX575-307 was a 1:1 randomized study in the US in 435 patients with dialysis, 
comparing  the  s.c.  administration  of  HX575  to  the  US-licensed  epoetin  alfa  Epogen/Procrit  (in  vials; 
designed for US). The primary objective of the study was to demonstrate equivalence in efficacy at the end 
of  the  initial  anemia  correction  period,  and  also  to  evaluate  the  incidence  of  antibody  formation  against 
HX575 and the safety profile over 52 weeks. 
No NAbs or PRCAs were detected in either study. 
2.5.  Discussion 
HX575  is  currently  approved  in  all  countries  of  European  Economic  area  (EEA).  It  has  since  received 
marketing authorization in 37 non EEA countries via national registration. 
The  extensive  post-marketing  safety  data  of  HX575  as  compiled  in  Sandoz’s  global  safety  database  are 
estimated to cover 283,227,200 patient-days (by 31-Aug-2017). Based on the post marketing data sources 
such as spontaneous individual case safety reports (ICSRs), including reports from healthcare professionals, 
consumers,  scientific 
literature,  and  competent  authorities 
(worldwide)  and 
from  solicited 
non-interventional  ICSRs  including  those  from  non-interventional  studies,  it  can  be  concluded  that  the 
safety profile of HX575 remains to be positive and in line with the previous cumulative experience and the 
safety information provided in the reference safety information for erythropoietin. 
PRCA has been previously identified as a safety concern with subcutaneous usage of epoetins alfa in chronic 
kidney disease patients. HX575 has been authorised for s.c. route of administration in patients with CKD 
induced  anaemia.  The  Non-Interventional  Post-Authorization  Safety  Study  (NI-PASS)  HX575-507  was 
initiated in 2017 as appropriate measure to identify any risk associated with the s.c. administration route of 
HX575 in CKD patients under real-life post-approval conditions, including PRCA risk, a known treatment 
effect of the reference product. This NI-PASS study concept is part of the EU RMP. 
In  the  frame  of  the  new  indication,  the  RMP  provided  and  the  section  4.8  of  the  SmpC  were  updated 
accordingly. 
2.6.  Risk management plan 
The MAH has submitted updated RMP version 17.0 in order:  
• 
• 
to include the new indication of symptomatic anaemia in patients with low or intermediate-1-risk 
MDS; 
to include the Direct Healthcare Professional Communication (DHPC) on severe cutaneous adverse 
reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis 
(TEN); 
Assessment report  
EMA/CHMP/549796/2018 
Page 10/16 
 
  
  
• 
to be in line with the current “Guideline on good pharmacovigilance practices (GVP) Module V – Risk 
Management systems” and the “Guidance on format of the risk management plan (RMP) in the EU” 
effective on 31 Mar 2017. 
The DHPC regarding the risk of SCARs including Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) with epoetins was punctually disseminated to healthcare professionals on September 2017 
(EPITT No 18846, adoption of PRAC recommendation on 6th July 2017). Additionally, as part of final PRAC 
recommendation of the EPITT signal, this risk was implemented in sections 4.4 and 4.8 of the EU-SmPC of 
epoetin alpha containing products (including Binocrit). Therefore, at this time, the SCARs associated with 
epoetin alpha have been well established and characterised and no further characterisation by additional risk 
minimisation measures or pharmacovigilance activities is needed. As a result, the MAH updated the RMP 
(finally agreed version 17.1) and removed SCARs and the associated DHPC from the content of the RMP. 
New text marked as underlined, deletions marked as strikethrough: 
Safety concerns 
Summary of safety concerns 
Important identified risks 
Pure Red Cell Aplasia (PRCA) 
Thromboembolic events 
Hypertension/hypertensive crisis 
Seizure 
Premature death  
Hypersensitivity reactions (including anaphylactic 
reactions) 
Hyperkalemia 
Severe cutaneous adverse reactions (SCARs) 
Important potential risks 
Tumor growth potential 
Congestive heart failure 
Misuse 
Missing information 
Safety in pregnancy and lactation 
Safety in children 
Pharmacovigilance plan 
Study/Status  
Summary of 
objectives 
Safety concerns 
addressed 
Milestones   Due dates  
Category 3 - Required additional pharmacovigilance activities  
Assessment report  
EMA/CHMP/549796/2018 
Page 11/16 
 
  
  
 
 
 
Study/Status  
NIS-PASS (MEA 13.5) 
Ongoing 
TRIGONS study MEA 18; 
HX575-502 
pharmacoepidemiological 
study MEA 18 is related 
to LEG027/028. 
Not  applicable/Pending 
EMA decision. 
Summary of 
objectives 
Safety concerns 
addressed 
Milestones   Due dates  
PRCA and other rare 
AEs of special 
interest, overall 
safety of HX575 in 
s.c. administration 
in CKD patients 
Thrombotic events 
Tumor growth 
potential 
To increase further 
confidence in the real 
world of the safe and 
efficacious use of 
Sandoz epoetin alfa 
administered 
subcutaneously in 
patients with CKD 
associated anemia, 
especially with 
regards to PRCA and 
loss of efficacy. The 
study primary 
objective is to 
evaluate rare AEs like 
PRCA and other AEs of 
special interest 
To evaluate the 
within-treatment and 
long-term safety of de 
novo treatment with 
HX575 or RBC 
transfusion for 
managing 
chemotherapy 
induced anemia in 
ovarian cancer 
patients.  
Study start 
date 
12 Apr 2017 
N/A: upon 
completion of 
2500 subjects 
and data analysis 
Feb 2023. 
Twelve months 
after end of data 
collection 
N/A 
Analyses 
after 1000 
and 2500 
patients 
enrolled 
Final report 
(planned) 
Pending 
EMA 
decision.  
In 
Assessment 
report dated 
Jan 2014 
the CHMP 
agreed to 
wait for the 
results of 
currently 
ongoing 
clinical and 
non-clinical 
studies by 
Amgen and 
Roche 
respectively 
before 
deciding on 
further 
steps. 
Risk minimisation measures 
Safety concern 
Risk minimisation measures 
Pharmacovigilance activities 
Important identified risks 
Pure Red Cell Aplasia 
Routine risk minimization measures: 
(PRCA) 
SmPC Sections 4.3, 4.4, 4.8.  
PL Section 2  
Legal status: Prescription only 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: 
NIS-PASS (MEA 13.5) 
Thromboembolic events 
Routine risk minimization measures:  Routine pharmacovigilance activities 
beyond adverse reactions reporting 
Assessment report  
EMA/CHMP/549796/2018 
Page 12/16 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety concern 
Risk minimisation measures 
SmPC Sections 4.3, 4.4, 4.8 and 5.1.  
PL Section 3.  
Legal status: Prescription only 
Hypertension/hypertensive 
Routine risk minimization measures: 
crisis 
SmPC Sections 4.3, 4.4, 4.8   
PL Section 3.  
Legal status: Prescription only 
Seizure 
Routine risk minimization measures: 
SmPC Sections 4.4, 4.8   
Legal status: Prescription only 
Premature death  
Routine risk minimization measures: 
SmPC Sections 4.4, 4.8 and 5.1.  
PL Section 2.  
Legal status: Prescription only 
Hypersensitivity reactions 
Routine risk minimization measures: 
(including anaphylactic 
reactions) 
SmPC Sections 4.3 and 4.8.   
Legal status: Prescription only 
Hyperkalemia 
Routine risk minimization measures: 
SmPC Sections 4.4 , 4.8. 
PL Section 3.  
Legal status: Prescription only 
Pharmacovigilance activities 
and signal detection: None 
Additional pharmacovigilance 
activities: 
TRIGONS study, study MEA 18; 
HX575-502, 
pharmacoepidemiological 
study, MEA 18 is related to 
LEG027/028 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Severe cutaneous adverse 
reactions (SCARs) 
Routine risk minimization measures: 
Routine pharmacovigilance activities 
SmPC Sections 4.4 , 4.8.  
PL Section 2  
Legal status: Prescription only 
Additional risk minimization 
measures: DHPC 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Important potential risks 
Tumor growth potential 
Routine risk minimization measures: 
SmPC Sections 4.4, 4.5, 5.1 and 5.3 
Legal status: Prescription only 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Assessment report  
EMA/CHMP/549796/2018 
Page 13/16 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety concern 
Risk minimisation measures 
Congestive heart failure 
Routine risk minimization measures: 
SmPC Section 5.1 
PL Section 2.  
Legal status: Prescription only 
Misuse 
Routine risk minimization measures: 
SmPC section: None 
PL section: None 
Legal status: Prescription only 
Missing information 
Safety in pregnancy and 
Routine risk minimization measures: 
lactation 
SmPC Section 4.6  
PL Section 2 
Legal status: Prescription only 
Safety in children 
Routine risk minimization measures: 
SmPC Section 4.8 
PL section: None 
Legal status: Prescription only 
Conclusion 
Pharmacovigilance activities 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
Routine pharmacovigilance activities 
beyond adverse reactions reporting 
and signal detection: None 
Additional pharmacovigilance 
activities: None 
The CHMP and PRAC considered that the risk management plan version 17.1 is acceptable provided that the 
revision of the list of safety concerns as per new RMP template Rev.2 should be done by the MAH as a post 
approval commitment (at the next regulatory opportunity or within 6 months at the latest after opinion). 
2.7.  Update of the Product information 
As a result of this variation, sections 4.1, 4.2, 4.4 and 4.8 of the SmPC are being. The Package Leaflet (PL) 
is updated accordingly. 
Please refer to Attachment 1 which includes all agreed changes to the Product Information. 
3.  Benefit-Risk Balance 
HX575 is a biosimilar medicinal product. A MA was granted in August 2007 under the brand names Binocrit, 
Epoetin alfa HEXAL, and Abseamed.  
This Application is a type II variation to extend the indications of HX575 to the treatment of symptomatic 
anaemia (haemoglobin concentration of 10≤ g/dL= in adult with low- or intermediate- 1 risk primary 
myelodysplastic syndromes (MDS)and low serum erythropoietin (<200 IU/mL). This last indication was 
approved for the originator product (Eprex/Erypo) through the Mutual Recognition Procedure with France 
acting as RMS in 2017.  
Assessment report  
EMA/CHMP/549796/2018 
Page 14/16 
 
  
  
 
 
 
 
 
The initial originator Application was mainly based on the EPOANE 3021 study. Since the exclusivity 
protection for EPOANE 3021 data has been granted for the period of one year starting from the 27th of April 
2017, the MAH is submitting a type II variation after the one-year exclusivity being expired. 
This variation is overall in agreement with the following EMA guidelines:  
- 
- 
- 
guideline on similar biological medicinal products (EMEA/CHAMP/437/04 Rev. 1). 
guideline on similar medicinal products containing biotechnology-derived proteins as active substance: 
non-clinical and clinical issues (EMEA/CHAMP/BMWP/42832/2005 Rev. 1). 
guideline  on  non-clinical  and  clinical  development  of  similar  biological  medicinal  products  containing 
recombinant erythropietins (Revision) (EMEA/CHMP/BMWP/301636/2008 Corr.). 
According to guideline on similar biological medicinal products, biosimilarity between HX575 and the 
reference product has been already demonstrated in at least one pivotal indication. The scientific 
justification provided to extrapolate the biosimilary to the other indication is appropriate. 
Overall, the efficacy and safety of HX575 is justified by the mechanism of action of the active substance of 
the reference product which is the same in each approved indication. Consequently, the efficacy and safety 
similarity which was mainly demonstrated in renal anaemia patients allow an extrapolation to the extension 
of indication of the reference medicinal product with the same route of administration. 
The RMP is updated to include the new indication and to remain in line with the current “guideline on good 
pharmacovigilance practices (GVP) module V- risk management systems” and the “guidance on format of 
risk management plan (RMP) in the EU”.  
The DHPC regarding the risk of SCARs including Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) with epoetins was punctually disseminated to healthcare professionals on September 2017 
(EPITT No 18846, adoption of PRAC recommendation on 6th July 2017). Additionally, as part of final PRAC 
recommendation of the EPITT signal, this risk was implemented in sections 4.4 and 4.8 of the EU-SmPC of 
epoetin alpha containing products (including Binocrit). Therefore, at this time, the SCARs associated with 
epoetin alpha have been well established and characterised and no further characterisation by additional risk 
minimisation measures or pharmacovigilance activities is needed. As a result, the MAH updated the RMP 
(finally agreed version 17.1) and removed SCARs and the associated DHPC from the content of the RMP. 
Moreover, the MAH submitted the EU-RMP v17.0 (and finally agreed version 17.1) supposed to be in line 
with the new GVP module V rev 2. Please note that substantial change was provided regarding the definition 
of important identified/potential risks in GVP module V rev 2. The revision of the list of safety concerns as per 
new template should be done by the MAH as a post approval commitment (at the next regulatory 
opportunity or within 6 months at the latest after opinion).  
In conclusion, the overall benefit-risk balance of HX575 in the treatment of symptomatic anaemia 
(haemoglobin concentration of 10≤ g/dL= in adult with low- or intermediate- 1 risk primary myelodysplastic 
syndromes (MDS)and low serum erythropoietin (<200 IU/mL), is positive. 
4.  Recommendations 
Outcome 
Based on the review of the submitted data, the CHMP considers the following variation acceptable and 
therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following 
change: 
Assessment report  
EMA/CHMP/549796/2018 
Page 15/16 
 
  
  
 
Variation accepted 
Type 
Annexes 
affected 
C.I.2.b  
C.I.2.b - Change in the SPC, Labelling or PL of a 
Type II 
I, IIIA, IIIB 
generic/hybrid/biosimilar products following assessment of 
and A 
the same change for the reference product - Change(s) 
require to be further substantiated by new additional data 
to be submitted by the MAH  
Extension of indication to include the treatment of symptomatic anaemia (haemoglobin concentration of 
≤ 10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have 
low serum erythropoietin (< 200 mU/ml) for Binocrit, Epoetin alfa Hexal and Abseamed; as a consequence, 
sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated with safety and efficacy information. The Package Leaflet 
and the risk management plan (finally agreed version 17.1) are updated in accordance. In addition, the 
worksharing applicant (WSA) took the opportunity to align information with the reference medicinal product 
and with the EC guideline on Excipients, to improve the quality and readability of the translations in the 
product information and to update the Annex A in line with EMA guideline. 
5.   EPAR changes 
The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 
"steps after the authorisation" will be updated as follows: 
Scope 
Extension of indication to include the treatment of symptomatic anaemia (haemoglobin concentration of 
≤ 10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have 
low serum erythropoietin (< 200 mU/ml) for Binocrit, Epoetin alfa Hexal and Abseamed; as a consequence, 
sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated with safety and efficacy information. The Package Leaflet 
and the risk management plan (finally agreed version 17.1) are updated in accordance. In addition, the 
worksharing applicant (WSA) took the opportunity to align information with the reference medicinal product 
and with the EC guideline on Excipients, to improve the quality and readability of the translations in the 
product information and to update the Annex A in line with EMA guideline. 
Summary 
Please refer to Scientific Discussion Abseamed-H-C-WS-1406, Binocrit-H-C-WS-1406, Epoetin alpha 
Hexal-H-C-WS-1406 
Assessment report  
EMA/CHMP/549796/2018 
Page 16/16 
 
  
  
 
 
